ELEV 241220 2.50P (ELEV241220P2500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

ELEV241220P2500

Watchlist

1.90
0.000.00%

15min DelayClose Dec 20 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Analysts' Top Healthcare Picks: Opus Genetics (IRD), Elevation Oncology (ELEV)
TipRanksDec 15 10:40 ET · Ratings
H.C. Wainwright Maintains Elevation Oncology(ELEV.US) With Buy Rating, Maintains Target Price $6
Moomoo NewsDec 13 06:31 ET · Ratings
Promising Pipeline and Strategic Advances Support Buy Rating for Elevation Oncology
TipRanksDec 13 06:15 ET · Ratings
Elevation Oncology Reports Nomination Of EO-1022 As Its HER3 ADC Development Candidate
BenzingaDec 12 07:42 ET
Express News | Synaffix: Co Is Eligible to Receive up to $368 Mln in Upfront and Clinical, Regulatory, and Commercial Milestone Payments
ReutersDec 12 07:39 ET
Express News | Elevation Oncology Inc: Expects to Present Eo-1022 Preclinical Data in 1H 2025 and to File an Ind Application in 2026
ReutersDec 12 07:30 ET

Comments

Jaguar8

Dec 12 06:34

NEWS

$Elevation Oncology (ELEV.US)$
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors
Thursday, 12th December at 7:30 am
-- EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload –
-- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin E™ linke...

Jaguar8

Dec 5 06:48

NEWS

$Elevation Oncology (ELEV.US)$
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024
Thursday, 5th December at 7:30 am
-- Treatment with both combination regimens demonstrates synergistic anti-tumor activity, supporting planned combination strategy for EO-3021 in patients with gastric or gastroesophageal junction (GEJ) cancer –
-- On-track to initiate dosing in com...

Trytosaveabit

Dec 5 06:42

Update

$Elevation Oncology (ELEV.US)$ Elevation Oncology Announced New Preclinical Data Demonstrating The Combination Potential Of EO-3021, A Claudin 18.2 Antibody-drug Conjugate, With VEGFR2 or PD-1 Inhibitors, The Data Will Be Presented At The European Society For Medical Oncology Immuno-oncology Annual Congress 2024

porsh

Oct 22 13:01

$Elevation Oncology (ELEV.US)$ when will you squeeze

Jaguar8

Sep 23 06:30

NEWS

$Elevation Oncology (ELEV.US)$
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2